Rationale Several randomised controlled trials support the provision of early pulmonary rehabilitation (PR) following hospitalisation for acute exacerbation of chronic obstructive pulmonary disease ...

Introduction In patients with chronic obstructive pulmonary disease (COPD), the risk of certain cardiovascular (CV) events is increased by threefold to fivefold in the year following acute ...

With COPD, you can be at risk for serious complications that not only put your health in jeopardy, but also could be fatal. We'll share tips for preventing them.

Learn about COPD medications, including bronchodilators, steroids, and combination treatments. Understand how they work, their side effects, and ways to manage COPD effectively.

Home-based pulmonary rehabilitation has been slowly gaining momentum for chronic obstructive pulmonary disease (COPD), but access is still a challenge. "The science shows that there is greater ...

Eating healthy fats, dairy, and protein and incorporating nutritional shakes can help with gaining weight. Weight loss may make breathing more difficult.

Tezepelumab has received an FDA breakthrough therapy designation as a maintenance treatment for patients with moderate to very severe COPD characterized by an eosinophilic phenotype, according to ...

WebMD's COPD Health Center provides in-depth information on chronic obstructive pulmonary disease including symptoms, causes, treatment options, diagnosis, and tests.

GSK has said new data leads it to believe Nucala will be "highly competitive" with rival biologic Dupixent in COPD if it gets approved by the FDA.

Can vitamin D, omega-3s, turmeric, and other supplements ease COPD symptoms? Find out which vitamin remedies may help with COPD treatment.

GSK just hit one of its main objectives for 2025 after getting FDA approval of anti-IL-5 antibody Nucala as a treatment for chronic obstructive pulmonary disease (COPD). Nucala (mepolizumab) has ...

Abstract Summary Pharmacological enhancement of endoplasmic reticulum (ER) proteostasis is an attractive strategy to mitigate pathology linked to etiologically-diverse protein misfolding diseases.